Trials / Completed
CompletedNCT00560703
Treatment of Patients With Blepharitis and Facial Rosacea
Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients With Facial Rosacea
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | COL-101 (doxycycline, USP) capsules | 40mg, once per day for 84 days |
| DRUG | placebo | sugar capsule |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-05-01
- Completion
- 2009-07-01
- First posted
- 2007-11-20
- Last updated
- 2021-02-18
- Results posted
- 2012-01-11
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00560703. Inclusion in this directory is not an endorsement.